Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention: NICE technology appraisal guidance.
Hill
R A
RA
Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence, London, UK. ruaraidh.hill@nice.org.uk
Chung
H
H
George
E
E
Longson
C
C
Stevens
A
A
D054058:Acute Coronary Syndrome / Q000191:economics / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000627:therapeutic use*
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride